no code implementations • 24 Apr 2021 • Cameron Mura, Saskia Preissner, Robert Preissner, Philip E. Bourne
We consider the recent surge of information on the potential benefits of acid-suppression drugs in the context of COVID-19, with an eye on the variability (and confusion) across the reported findings--at least as regards the popular antacid famotidine.